Advancements in COPD treatment are offering relief to thousands of Kentuckians by targeting inflammation directly without the ...
This research document defines 'disease stability' as a new therapeutic indicator for chronic obstructive pulmonary disease (COPD) and verifies its clinical significance. Stability is presented as an ...
An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market ...
10don MSN
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales ...
Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk ...
Background Pulmonary rehabilitation (PR) is the cornerstone of non-pharmacological treatment for chronic obstructive ...
Precision medicine approaches for chronic obstructive pulmonary disease (COPD) are lagging, creating gaps in care and leaving ...
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
A new drug shows promise in reducing the symptoms of COPD, one of the top 10 leading cause of death in the U.S., according to ...
Persistent access barriers leave many treatment candidates without advanced therapy as physicians look for stronger disease ...
Researchers conducted a cohort study to compare lung cancer risk among patients with COPD and T2DM using SGLT2 inhibitors vs sulfonylureas.
AstraZeneca’s experimental COPD drug has significantly reduced flare-ups in two late-stage trials, making FDA approval in ...
The goals of COPD treatment are to reduce symptoms and symptom flare-ups. "This can be done through a combination of lifestyle changes and treatment options in consultation with your doctor," says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results